We are your trusted health partner. Local doorstep deliveries is within the hour .We are Licensed and Regulated by the Pharmacist's Council of Nigeria(PCN).Prices displayed here may differ due to inflation.
Bortezomib 3.5mg is a prescription-only, high-potency targeted oncology medication. It belongs to a class of drugs known as proteasome inhibitors. It is administered exclusively by qualified healthcare professionals as an injection to treat Multiple Myeloma (a cancer of the plasma cells in the bone marrow) and Mantle Cell Lymphoma (an aggressive type of non-Hodgkin lymphoma).
The suffix IP denotes that the medication is manufactured to meet the rigorous quality parameters of the Indian Pharmacopoeia. It is supplied as a sterile, dry lyophilized powder containing 3.5mg of Bortezomib inside a single-dose vial, which must be carefully dissolved (reconstituted) immediately before administration.
Bortezomib acts as a precise molecular block inside cancer cells, choking off their internal waste disposal system:
Inhibits the 26S Proteasome: Every cell contains microscopic structural enzymes called proteasomes, which act like garbage disposals to break down damaged or excess proteins. Bortezomib binds tightly to and blocks the 26S proteasome pathway.
Triggers Protein Toxic Overload: Because multiple myeloma and lymphoma cells are hyperactive and produce massive amounts of abnormal proteins, blocking their waste disposal causes these toxic proteins to build up rapidly inside the cell.
Forces Cancer Cell Self-Destruction: Suffocated by its own internal waste material, the cancer cell can no longer send growth signals and undergoes rapid programmed cell death (apoptosis), while healthy cells are standardly able to recover.
Multiple Myeloma: First-line treatment for newly diagnosed adults (standardly combined with other medications like thalidomide, lenalidomide, or dexamethasone), or as a secondary therapy for patients whose cancer has returned (relapsed) after previous treatments.
Mantle Cell Lymphoma: Treating aggressive mantle cell lymphoma in adults, either as a first-line option in combination regimens or for relapsed disease.
Bortezomib 3.5mg can be given either as a Subcutaneous (SC) injection under the skin or a rapid Intravenous (IV) injection into a vein.
🚨 Absolute Contraindication: Bortezomib is strictly fatal if given into the fluid surrounding the spinal cord (intrathecal injection). The medical team will use explicit labeling and double-check protocols to guarantee it is never given intrathecally. Subcutaneous administration is standardly preferred by oncologists as it drastically reduces the risk and severity of nerve damage.
It can cause or worsen nerve damage, leading to burning pain, numbness, tingling, or weakness in the hands and feet. Your oncology team will screen your nerve responses before every cycle; if neuropathy develops, your doctor will reduce the dose or switch you completely to the subcutaneous injection route.
Because this drug modifies your bone marrow and immune cells, it heavily increases your risk of developing a painful outbreak of shingles (Herpes Zoster reactivation). To completely prevent this, oncologists standardly prescribe a daily preventive antiviral pill (such as Acyclovir) to take throughout your entire treatment course.
Pregnancy and Breastfeeding: Bortezomib is strictly contraindicated. It causes severe fetal toxicity or miscarriage. Highly effective birth control must be used by both male and female patients during treatment and for at least 3 months after the final dose.
Severe baseline liver impairment.
Strictly Professional Clinical Use Only: The 3.5mg dry powder vial must only be dissolved using sterile 0.9% Sodium Chloride (Normal Saline). The volume of saline used depends strictly on the intended injection route:
For Subcutaneous (SC) Injection: Dissolve the powder with exactly 1.4mL of saline, creating a concentrated solution of 2.5mg/mL. It is injected into the fat layer of the thigh or abdomen, rotating the site with every dose.
For Intravenous (IV) Injection: Dissolve the powder with exactly 3.5mL of saline, creating a solution of 1.0mg/mL. It is given as a rapid 3-to-5 second injection directly into a vein or IV line.
The Routine Schedule: Bortezomib is standardly given in cycles (such as a 3-week cycle where the injection is given on days 1, 4, 8, and 11, followed by a 10-day rest period). At least 72 hours must always elapse between any two doses of Bortezomib to allow your body to clear the medicine safely.
As your system interacts with this targeted proteasome inhibitor, you will experience typical updates:
Peripheral Neuropathy: Numbness, tingling, a "pins-and-needles" burning sensation, or muscle weakness in your fingers and toes.
Gastrointestinal shifts, including temporary diarrhea, severe constipation, nausea, vomiting, or a loss of appetite.
Thrombocytopenia and Anemia: A temporary drop in blood platelets (increasing the risk of easy bruising or bleeding) and red blood cells (causing generalized fatigue). Platelet levels standardly drop during the injection weeks and recover during the rest period.
Postural Hypotension: A sudden drop in blood pressure when standing up, which can cause lightheadedness or brief dizziness.
What signs should I watch out for at home that require immediate emergency evaluation?
Because Bortezomib suppresses your bone marrow and alters blood metrics, you must contact your oncology clinic or rush to the nearest emergency room immediately if you develop a fever of 38°C (100.4°F) or higher, uncontrollable chills, unexpected bruising, pinpoint red spots on your skin (petechiae), blood in your stool or urine, or a sudden, severe worsening of numbness and burning in your legs.
Can I take over-the-counter pain relievers or supplements during treatment?
You must consult your oncologist before taking any new medications. You must strictly avoid green tea and green tea extracts, as well as Vitamin C supplements, during your Bortezomib cycles. Compounds in green tea and high-dose Vitamin C can bind directly to the bortezomib molecule, completely blocking its ability to destroy cancer cells and rendering your chemotherapy ineffective.
How should the unopened 3.5mg vial be stored before use?
Unopened vials should be kept inside their original outer cardboard carton to protect the lyophilized powder from direct light. Store the box in a cool room strictly below 25°C. Reconstituted solutions should ideally be administered immediately, but can be held for up to 8 hours if stored in a clean syringe.
Advanced targeted oncological therapies require absolute temperature regulation, secure supply chain tracking, and strict anti-counterfeit validation to protect ingredient potency and ensure treatment success. Institutional hospital procurement, emergency day-case stock replenishment, and verified batch delivery can be securely coordinated through Sanlive Pharmacy & Stores for rapid, climate-controlled, and tamper-evident delivery directly to registered cancer centers, teaching hospitals, and accredited private oncology facilities within Lagos, Abuja, Port Harcourt, and nationwide via our authenticated specialty clinical logistics networks.
Important Notice: This information is for educational and institutional procurement support purposes only. Bortezomib 3.5mg is an ultra-high-potency cytotoxic targeted agent. All reconstitution, calculation, and clinical administration must be managed exclusively under the direct physical care of a registered Consultant Oncologist or oncology practitioner. If a patient experiences severe difficulty breathing, sudden chest tightness, or severe dizziness immediately following an injection, activate emergency life-support protocols immediately.
No reviews yet — be the first!
Log in to write a review.
.jpg)
